Mer­ri­mack CEO, CFO bow out, months af­ter last clin­i­cal drug fiz­zles

Richard Pe­ters Mer­ri­mack

Two months ago, Mer­ri­mack was forced to aban­don its last drug in clin­i­cal tri­als, af­ter an ear­ly-stage study showed that treat­ment with the drug, MM-310, was cu­mu­la­tive­ly tox­ic to pa­tients, de­spite tri­al pro­to­col amend­ments. On Mon­day, the ex-Sanofi ex­ec­u­tive the Cam­bridge, Mass­a­chu­setts-based com­pa­ny ush­ered in 2017 to re­vive its for­tunes de­part­ed.

In 2015, Mer­ri­mack $MACK se­cured FDA ap­proval for its pan­cre­at­ic can­cer drug — Onivyde, which had a dis­ap­point­ing de­but. It was sold to Ipsen in 2017, in par­al­lel to a re­struc­tur­ing, which cul­mi­nat­ed in a new CEO — Richard Pe­ters — a slim­mer work­force and three pipeline prospects: MM-141, MM-121 and MM-310. Each of these drugs has now been rel­e­gat­ed to the scrap heap.

Jean Franchi LinkedIn

In April, af­ter ax­ing MM-310, the com­pa­ny said it was cut­ting jobs, but did not spec­i­fy how many. It now has two pre­clin­i­cal drugs — MM-401 and MM-201 — left in its ar­se­nal. Last No­vem­ber, the com­pa­ny slashed its work­force by 60%, weeks af­ter dis­clos­ing MM-121, or serib­an­tum­ab, added to do­c­etax­el made no dif­fer­ence to pa­tients with non-small cell lung can­cer. This slash and burn was pre­ced­ed by an­oth­er flop in 2018. The com­pa­ny rid it­self of MM-141 af­ter it failed a Phase II com­bo study in pan­cre­at­ic can­cer.

On Mon­day, Mer­ri­mack said Pe­ters was leav­ing the com­pa­ny. He will re­ceive $743,746.21 — 12 months of his base salary — in sev­er­ance, a pro-rat­ed bonus of $294,891.15, and the com­pa­ny will con­tin­ue pay­ing a share of the pre­mi­um for Pe­ters’ health and den­tal in­sur­ance for a pe­ri­od of one year (un­less he changes his cov­er­age). Pe­ters on June 25 agreed to con­sult with Mer­ri­mack at a rate of $30,989.43 per month to as­sist with its re­port­ing oblig­a­tions and the ad­min­is­tra­tion of re­main­ing as­sets.

Gary Crock­er Crock­er Ven­tures

Apart from Pe­ters, CFO Jean Franchi and board chair­man Gary Crock­er are al­so de­part­ing. Franchi gets $415,002.70 in sev­er­ance, a pro-rat­ed bonus of $77,544.30, a share paid for health and den­tal in­sur­ance, and con­sult­ing fees of $17,291.78 per month.

As of March 31, Mer­ri­mack had an ac­cu­mu­lat­ed deficit of $533.7 mil­lion; cash, cash equiv­a­lents and mar­ketable se­cu­ri­ties of $58.5 mil­lion; and said it ex­pects to con­tin­ue to gen­er­ate op­er­at­ing loss­es in the fore­see­able fu­ture in a fil­ing post­ed in May.

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

News brief­ing: Gilead part­ner Gala­pa­gos sells off CRO for $37M; Polyphor bags $3.3M from CF Foun­da­tion

Close Gilead ally Galapagos is selling off one of its contract research organizations to a Polish pharma company.

Galapagos has agreed to sell 100% of the outstanding shares in the CRO Fidelta to Selvita, in a deal worth roughly $37 million expected to close in the first week of January. The acquisition is expected to nearly double Selvita’s revenues, the company says, as well as expand its drug discovery efforts.

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.

The Danish biotech reported Tuesday that it decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. According to the company:

While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

Michelle Longmire, Medable CEO (Jeff Rumans)

Med­able gets $91M for vir­tu­al clin­i­cal tri­als, bring­ing to­tal raise to $136M

As biotechs look to get clinical studies back on track amid the pandemic, Medable returned to the venture well for the second time this year, bagging a $91 million Series C to build out its virtual trial platform.

The software provider recently launched three new apps for decentralizing clinical trials, and saw a 500% revenue spike this year. And it isn’t alone. Back in August, Science 37 secured a $40 million round for its virtual trial tech, with support from Novartis, Sanofi Ventures and Amgen. Patients and researchers are taking a liking to the online approach, suggesting regulators could allow it to become a new normal even after the pandemic is over.

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

Ever since President Donald Trump floated the idea of using state-sponsored importation to lower drug prices, PhRMA has made its opposition abundant. Not only is the proposal dangerous and futile,  but the trade group has also argued that it may even be illegal.

Now that the FDA has issued its final rule permitting states to bring certain drugs from Canada, PhRMA is taking the government to court — just a few days before the rule is slated to take effect.